How neuroplastogens became the next frontier.
For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma, and addiction. That wave brought psilocybin, MDMA, ketamine clinics, and a flood of research interest. However, it was not adoptable by large patient bases.
What has emerged more recently as a result is a very different race. Scientists have long believed it may be possible to capture the therapeutic benefits that psychedelics trigger in the brain without producing hallucinations. These new compounds fall under the umbrella of neuroplastogens, a group of small molecules engineered to stimulate structural and functional plasticity in the brain without the hallucinations associated with classic psychedelics.
The shift is important because it addresses a simple question. What if the future of psychedelic medicine is not psychedelic at all?
Delix and the Validation of the Category
Delix Therapeutics is one of the clearest examples of how far this space has come. The company recently reported early clinical data for DLX001, also known as zalsupindole. Participants with major depressive disorder showed meaningful reductions in depressive symptoms without any hallucinogenic or dissociative effects. Most surprising of all was the regulatory response. The FDA cleared a Phase II design that allows for at-home self-administration, which is a sign that regulators may be warming to compounds that remove the intensity and logistical weight of classic psychedelic therapy.
In the background of these results is a broader scientific story. Delix has demonstrated in preclinical models that DLX001 can promote plasticity in a manner similar to agents like ketamine or psilocybin. If those findings continue to hold up in human studies, the entire field may enter a new chapter, bringing hope to millions of patients worldwide.
Gilgamesh, AbbVie, and the Arrival of Major Pharma
The excitement around neuroplastogens is not limited to the clinic. Earlier this year AbbVie acquired assets from Gilgamesh Pharmaceuticals for a sum that signaled very strong confidence in this category. Gilgamesh had been developing both psychedelic and non-psychedelic compounds, including GM1020 and GM2505, each designed to target pathways involved in mood and circuit-level regulation.
The acquisition did not happen in a vacuum. It followed years of increasing interest from large pharmaceutical companies seeking treatments for depression and anxiety that are differentiated, scalable, and economically attractive. A nonhallucinogenic approach fits neatly into that goal because it avoids the two bottlenecks that have slowed psychedelic therapy.
- The need for supervised dosing with trained facilitators.
- The variability of the subjective experience makes consistent outcomes harder to control.
AbbVie’s move signaled a turning point. Major pharma appears ready to place real capital behind neuroplasticity-focused therapeutics, and the rest of the field has followed that signal closely.
Enveric Biosciences and the Push to Expand the Chemical Playground
Another company shaping the conversation is Enveric Biosciences. Enveric has built a large library of nonhallucinogenic compounds through its discovery platform and has been steadily securing patent protection around several classes of molecules. Its lead candidate, EB 003, is a nonhallucinogenic derivative of DMT designed to promote plasticity without inducing a trip.
More recently, Enveric received a fourth Notice of Allowance from the USPTO for its EVM401 series, which includes mescaline-inspired compounds engineered for plasticity without psychoactive effects. This growing set of patents shows how aggressively companies in the space are working to lock down chemical territory before the category reaches full commercial maturity.
Although Enveric has not yet entered Phase II studies like Delix, its pipeline strategy aligns with the same thesis that is driving investor attention. If you can separate plasticity from hallucination, you can create treatments that look and behave like conventional oral medications. That model is far easier to scale, far easier to reimburse, and far more attractive to large partners.
A Wider Field Begins to Take Shape
Delix, Gilgamesh, and Enveric are not alone. Several other companies are building variations of this concept.
- BetterLife Pharma has been developing nonhallucinogenic lysergic acid derivatives such as BETR LS1, which aims to stimulate plasticity without subjective effects.
- Mindset Pharma has explored chemically modified versions of psilocybin analogs with reduced psychoactive impact.
- Athira Pharma has been advancing compounds that target neurotrophic pathways related to plasticity, although in the context of cognitive disorders.
- Relmada Therapeutics has been pursuing nonhallucinogenic NMDA receptor modulators designed to capture the antidepressant potential of ketamine without dissociation.
What connects this ecosystem is not a single receptor or a single molecule type. It is the belief that the key to long-lasting therapeutic benefit lies in rebuilding or strengthening neural circuits rather than inducing the trip itself.
The Road Ahead
There is still debate within the scientific community about whether a psychedelic experience plays a necessary role in healing. Some argue that meaning-making, emotional release, and experiential learning are essential. Others believe the neurological machinery is the real driver and that the subjective experience merely accompanies bigger biological changes.
The reality may be somewhere in between. There is room for both paths. The difference is that neuroplastogens are designed to reach people who cannot or will not undergo a psychedelic journey, or who need something faster, simpler, and more accessible.
The question that hangs over the industry now is how fast the evidence will accumulate. If Delix’s upcoming Phase II trial confirms the early signals from DLX001, it may push regulatory agencies, payors, and investors to shift their focus even more strongly toward nonhallucinogenic compounds. With AbbVie’s acquisition, other major players are definitely feeling the pressure to follow.
For companies like Enveric that specialize in nonhallucinogenic chemistry, the timing could be powerful. A rising level of validation across the field may create opportunities for collaborations, licensing, or future acquisitions.
The neuroplastogen race is no longer theoretical. It is advancing through clinical data, intellectual property, and strategic capital. What began as a side branch of psychedelic science is quickly becoming one of the most competitive areas in neuropsychiatric drug development.
